Organic Active Ingredients TRIZ Cases

A hydrophobic hyaluronic acid aggregate with an association promoter sustains drug levels and solubilizes poorly water-soluble actives without toxic solvents.

An oxygen scavenger in the package prevents dronabinol oxidation, enabling room-temperature storage with longer shelf life and fewer impurities.

Administering deoxythymidine and deoxycytidine helps rebalance nucleotide pools, rescue mitochondrial DNA copy number, and improve TK2 deficiency outcomes.

New anti-sickling compound classes restore red blood cell morphology and reduce cytotoxic effects where current sickle cell therapies fall short.

Controlled oral minoxidil release maintains therapeutic serum levels for hair loss while reducing adverse effects and frequent application.

pH-controlled coupling and cyclization steps produce stable, high-purity sGC stimulators and intermediates suitable for scale-up.

Using cacao bean shell as a ceramide source, this case shows how extraction yields ceramide AP-rich compositions for skin and hair moisturization.

Blocking CXCR4 and beta-adrenergic signaling with G-CSF improves stem cell and lymphocyte mobilization while reducing G-CSF burden.

Stable hydrogel bead controls mimic live, dead, and apoptotic cells to improve flow cytometry viability calibration with less time and waste.

A pyranopyridine scaffold improves CYP11B2 selectivity to lower aldosterone while minimizing CYP11B1 inhibition and cortisol-related side effects.

A polymer solid dispersion keeps amorphous psilocybin from crystallizing, enabling faster onset with shorter action and better shelf stability.

A cobalt(III) Schiff base complex addresses platinum-drug toxicity by inducing cancer cell cycle arrest while remaining less toxic to normal cells.

Ionizable lipid LNPs encapsulate capsid-free DNA to improve delivery while reducing liver toxicity and avoiding immune barriers to redosing.

Novel formula (I) compounds inhibit eIF4A helicase to block oncogenic mRNA translation and reduce tumor growth in dysproliferative diseases.

Controlled benzo[c]chroman salt polymorphs improve chemical stability and processability, reducing precipitation and agglomeration during scale-up.

Specific GOS and HMO blends boost microbiota GABA synthesis to help relieve stress and mood disorders in infants and children.

An mGlu5 negative allosteric modulator reduces Dravet syndrome seizure frequency and severity without the seizure worsening seen with some treatments.

Novel amide compounds broaden CSF-1R inhibition to other type III kinases, extending therapeutic use beyond limits seen with existing inhibitors.

Using disodium 5,10-methylene-(6R)-THF with citrate and sulfate enables a lyophilizate that preserves purity, solubility, and room-temperature stability.

Novel compounds selectively activate 5HT2A while limiting 5HT2B and 5HT2C activity, improving metabolic stability and reducing side effects.

A lipid-based amide anesthetic complex extends postsurgical analgesia with rapid onset while reducing toxicity and repeat dosing.

A plant-derived β-1,4 galactan adjuvant reprograms tumor-associated macrophages to boost checkpoint inhibitor efficacy in low-response tumors.

Combining a PDE9 inhibitor with serotonergic psychedelic drugs extends therapeutic benefits, reduces side effects, and lowers treatment burden.

Specific crystalline 4-PivO-NMT chloride forms enable precise molecular weight determination and more reliable dosage formulation.

Hydrophobic fat-coated active yeast and degradable binders enable gradual rumen release, supporting intake, health, and milk production.

High-dose lipid binding protein complexes lower inflammatory cytokines in sepsis, AKI, and cytokine release syndrome.

Losartan prevents checkpoint-blocker-induced brain edema in glioblastoma while preserving anti-tumor immunity through MT-MMP reduction.

A daily tafoxiparin regimen promotes cervical ripening and spontaneous term labor while avoiding invasive induction and prostaglandin-related side effects.

Periodic LVOT gradient and LVEF checks guide myosin inhibitor dosing to limit systolic dysfunction and heart failure risk.

Crystalline forms of a menin inhibitor block the menin-MLL interaction, reducing oncogene expression and promoting cell differentiation.

Multi-receptor gamma-carbolines target residual schizophrenia symptoms, including negative and cognitive impairments, beyond acute control.

Sustained iontophoretic co-delivery of NAD+ and peptides extends therapeutic action, bypasses first-pass metabolism, and supports wound repair.

Amino acid and sugar additives help PNA formulations improve solubility and stability while lowering dosage needs for nucleic acid modulation.

An anhydrous nirogacestat route uses CDI activation and pyridine hydrobromide buffering to limit impurities and preserve stereochemistry.

Blocking bile acid reabsorption with ASBT inhibitors lowers serum bile acids in cholestasis and improves pruritus and liver markers.

Novel tafamidis crystalline and amorphous forms improve processing, stability, dissolution, and bioavailability for amyloidosis treatment.

A biodegradable ocular implant releases axitinib over months to maintain retinal therapy while reducing repeat injections and systemic exposure.

MTAP deletion drives MTA buildup that enables selective PRMT5 inhibition in tumor cells, improving anti-tumor activity while limiting blood toxicity.

A fluorophore-labeled RNA cap preserves capping efficiency and mRNA stability while enabling cellular tracking for vaccine and drug research.

Genotype-guided HSD17B13 inhibition targets PNPLA3 I148M patients to reduce liver disease risk and mitigate liver injury.

Macrocyclic compounds target KRAS G12D, G12V, NRAS, and HRAS with strong inhibition, good druggability, and lower toxicity.

A multi-ingredient botanical mixture targets allergic and autoimmune inflammation while minimizing side effects and cytochrome P450 interactions.

Formula (I) compounds drive autophagy while concentrating in CNS tissue over peripheral sites, addressing selective treatment of neurological disease.

A boswellia, perilla, quercetin, and plant extract mixture targets allergic inflammation while avoiding cytochrome P450 drug interactions.

Salt conversion to a succinate form improves solubility, stability, and oral bioavailability while preserving CDK4/6 inhibitory activity.

Fused bicyclic heterocyclic compounds improve 15-PGDH inhibition through modular substituent design for treating related diseases.

Dual MEK and B-Raf inhibition improves tumor-growth control by blocking the MAPK pathway more effectively than monotherapy.

Biocompatible microspheres carry biofilm-forming probiotics and prebiotics to improve gut persistence, reduce inflammation, and support infant neurodevelopment.